Home
User Guide
What's in a MalaCard Search Guide Our Sources
Analysis Tools
GeneCards GeneAnalytics GeneAlaCart PathCards VarElect TGex
News and Views Disease Lists/Categories
About
About MalaCards Our Publications Weizmann Institute LifeMap Discovery® Terms of Use MalaCards Team
MCID: LNG015
MIFTS: 48

Lingual-Facial-Buccal Dyskinesia

Categories: Neuronal diseases
Genes Variations Tissues Related diseases Publications Pathways Symptoms & Phenotypes Drugs
Sources

Aliases & Classifications for Lingual-Facial-Buccal Dyskinesia

About this section

MalaCards integrated aliases for Lingual-Facial-Buccal Dyskinesia:

Name: Lingual-Facial-Buccal Dyskinesia 12 15 72
Orofacial Dyskinesia 29 6
Oro-Facial Dyskinesia 12
Dyskinesias 44

Classifications:

MalaCards categories:
Anatomical: Neuronal diseases
See all MalaCards categories (disease lists)
ICD10: 33


External Ids:

Disease Ontology 12 DOID:9854
ICD9CM 35 333.82
MeSH 44 D020820
SNOMED-CT 68 49386006
ICD10 33 G24.4
UMLS 72 C0152115
Sources

Summaries for Lingual-Facial-Buccal Dyskinesia

About this section
MalaCards based summary : Lingual-Facial-Buccal Dyskinesia, also known as orofacial dyskinesia, is related to tardive dyskinesia and choreoacanthocytosis, and has symptoms including spasmodic torticollis An important gene associated with Lingual-Facial-Buccal Dyskinesia is CSTB (Cystatin B), and among its related pathways/superpathways are Peptide ligand-binding receptors and Circadian entrainment. The drugs Zonisamide and Aripiprazole have been mentioned in the context of this disorder. Affiliated tissues include brain, subthalamic nucleus and lung, and related phenotypes are behavior/neurological and nervous system

Sources

Related Diseases for Lingual-Facial-Buccal Dyskinesia

About this section

Diseases related to Lingual-Facial-Buccal Dyskinesia via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 775)
# Related Disease Score Top Affiliating Genes
1 tardive dyskinesia 32.9 DRD3 DRD2
2 choreoacanthocytosis 30.5 XK VPS13A
3 schizoaffective disorder 30.5 DRD3 DRD2
4 mood disorder 30.1 DRD4 DRD3 DRD2
5 personality disorder 30.0 DRD4 DRD2
6 movement disease 29.9 DRD3 DRD2
7 focal dystonia 29.9 DRD5 DRD2
8 tic disorder 29.9 DRD5 DRD4 DRD2
9 migraine with or without aura 1 29.8 DRD5 DRD3 DRD2
10 parkinson disease, late-onset 29.8 DRD3 DRD2 DRD1
11 dystonia 29.8 DRD5 DRD2 CSTB
12 restless legs syndrome 29.8 DRD3 DRD2
13 major depressive disorder 29.7 DRD4 DRD3 DRD2
14 gilles de la tourette syndrome 29.6 DRD5 DRD4 DRD2
15 early-onset schizophrenia 29.6 DRD2 DRD1
16 impulse control disorder 29.6 DRD4 DRD3 DRD2
17 disease of mental health 29.4 DRD4 DRD3 DRD2
18 drug dependence 29.3 DRD3 DRD2
19 migraine without aura 29.2 DRD4 DRD3 DRD2
20 bruxism 29.1 DRD5 DRD3 DRD2
21 delusional disorder 29.1 DRD4 DRD3 DRD2
22 substance abuse 28.8 DRD5 DRD4 DRD3 DRD2
23 obsessive-compulsive disorder 28.6 DRD4 DRD3 DRD2 DRD1
24 psychotic disorder 28.5 DRD4 DRD3 DRD2 DRD1
25 alcohol dependence 28.3 DRD4 DRD3 DRD2 DRD1
26 pathological gambling 27.9 DRD4 DRD3 DRD2 DRD1
27 attention deficit-hyperactivity disorder 27.7 DRD5 DRD4 DRD3 DRD2 DRD1
28 schizophrenia 27.4 DRD5 DRD4 DRD3 DRD2 DRD1
29 primary ciliary dyskinesia 12.7
30 episodic kinesigenic dyskinesia 1 12.7
31 paroxysmal nonkinesigenic dyskinesia, 3, with or without generalized epilepsy 12.6
32 ciliary dyskinesia, primary, 1 12.6
33 familial paroxysmal nonkinesigenic dyskinesia 12.6
34 ciliary dyskinesia, primary, 3 12.6
35 ciliary dyskinesia, primary, 9 12.6
36 adcy5-related dyskinesia 12.6
37 ciliary dyskinesia, primary, 7 12.6
38 ciliary dyskinesia, primary, 5 12.6
39 ciliary dyskinesia, primary, 17 12.6
40 ciliary dyskinesia, primary, 19 12.6
41 ciliary dyskinesia, primary, 20 12.6
42 ciliary dyskinesia, primary, 14 12.6
43 ciliary dyskinesia, primary, 15 12.6
44 ciliary dyskinesia, primary, 16 12.6
45 ciliary dyskinesia, primary, 35 12.6
46 ciliary dyskinesia, primary, 27 12.6
47 ciliary dyskinesia, primary, 21 12.6
48 ciliary dyskinesia, primary, 26 12.6
49 ciliary dyskinesia, primary, 28 12.6
50 ciliary dyskinesia, primary, 25 12.6

Graphical network of the top 20 diseases related to Lingual-Facial-Buccal Dyskinesia:



Diseases related to Lingual-Facial-Buccal Dyskinesia
Sources

Symptoms & Phenotypes for Lingual-Facial-Buccal Dyskinesia

About this section

UMLS symptoms related to Lingual-Facial-Buccal Dyskinesia:


spasmodic torticollis

MGI Mouse Phenotypes related to Lingual-Facial-Buccal Dyskinesia:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 behavior/neurological MP:0005386 9.5 CSTB DRD1 DRD2 DRD3 DRD4 DRD5
2 nervous system MP:0003631 9.23 CSTB DRD1 DRD2 DRD3 DRD4 DRD5
Sources

Drugs & Therapeutics for Lingual-Facial-Buccal Dyskinesia

About this section

Drugs for Lingual-Facial-Buccal Dyskinesia (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 210)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Zonisamide Approved, Investigational Phase 4 68291-97-4 5734
2
Aripiprazole Approved, Investigational Phase 4 129722-12-9 60795
3
Levetiracetam Approved, Investigational Phase 4 102767-28-2 441341
4
tannic acid Approved Phase 4 1401-55-4
5
Amantadine Approved Phase 4 768-94-5 2130
6
Benzocaine Approved, Investigational Phase 4 94-09-7, 1994-09-7 2337
7
Risperidone Approved, Investigational Phase 4 106266-06-2 5073
8
Olanzapine Approved, Investigational Phase 4 132539-06-1 4585
9
Amisulpride Approved, Investigational Phase 4 53583-79-2, 71675-85-9 2159
10
Galantamine Approved Phase 4 357-70-0 9651
11
Clozapine Approved Phase 4 5786-21-0 2818
12
Prednisone Approved, Vet_approved Phase 4 53-03-2 5865
13
chloroquine Approved, Investigational, Vet_approved Phase 4 54-05-7 2719
14
Azathioprine Approved Phase 4 446-86-6 2265
15
Dopamine Approved Phase 4 51-61-6, 62-31-7 681
16
Levodopa Approved Phase 4 59-92-7 6047
17
Carbidopa Approved Phase 4 28860-95-9 34359
18
Tetrabenazine Approved, Investigational Phase 4 58-46-8 6018
19
Varenicline Approved, Investigational Phase 4 249296-44-4 5310966
20
Acetylcholine Approved, Investigational Phase 4 51-84-3 187
21
Serine Approved, Nutraceutical Phase 4 56-45-1 5951
22 calcium channel blockers Phase 4
23 Serotonin Receptor Agonists Phase 4
24 Serotonin 5-HT1 Receptor Agonists Phase 4
25 Nootropic Agents Phase 4
26 Hormones Phase 4
27 Analgesics Phase 4
28 Anti-Infective Agents Phase 4
29 Analgesics, Non-Narcotic Phase 4
30 Peripheral Nervous System Agents Phase 4
31 Antiviral Agents Phase 4
32 Autonomic Agents Phase 4
33 Serotonin Agents Phase 4
34 Serotonin 5-HT2 Receptor Antagonists Phase 4
35 Serotonin Antagonists Phase 4
36 Antimalarials Phase 4
37 Antiparasitic Agents Phase 4
38 Antiprotozoal Agents Phase 4
39 Gastrointestinal Agents Phase 4
40 Antiemetics Phase 4
41 Dopamine Antagonists Phase 4
42 Hormone Antagonists Phase 4
43 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 4
44 Antidepressive Agents Phase 4
45 Dopamine D2 Receptor Antagonists Phase 4
46 Omega 3 Fatty Acid Phase 4
47 Antimetabolites Phase 4
48 Serotonin Uptake Inhibitors Phase 4
49 Antidepressive Agents, Second-Generation Phase 4
50 Cholinesterase Inhibitors Phase 4

Interventional clinical trials:

(show top 50) (show all 244)
# Name Status NCT ID Phase Drugs
1 An Open-Label Tolerability and Exploratory Efficacy Study of Zonisamide for Dyskinesias in Parkinson's Disease Unknown status NCT03034538 Phase 4 Zonegran;Zonegran
2 Aripiprazole for Pre-Existing Neuroleptic-Induced Tardive Dyskinesia: a Prospective 26-Week Observational Study Unknown status NCT00837707 Phase 4 aripiprazole
3 A Study of the Utility of Botulinum Toxin Type A for Pain in Advanced Parkinson's Disease Double Blind Placebo Control Crossover Pilot Study Unknown status NCT02472210 Phase 4 Botulinum Toxin
4 The Monitor of Serum Prolactin Level and Related Clinical Observations Among Individuals With Schizophrenia Spectrum Illnesses in a 3 Months Aripiprazole Trial Unknown status NCT00468533 Phase 4 Aripiprazole
5 Different Dyskinesias in Parkinson's Disease and Their Relation to Levodopa Pharmacokinetics Completed NCT00888186 Phase 4 levodopa/carbidopa
6 Efficacy and Safety of Levetiracetam Versus Placebo on Levodopa-induced Dyskinesias in Advanced Parkinson's Disease (LeLeDys Study) - A Multicenter, Randomized, Stratified, Double-blinded, Placebo-controlled Phase IV Study Completed NCT00307450 Phase 4 Levetiracetam
7 A Phase 4, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Potential for Clinical Dependence and Withdrawal Symptoms Associated With Valbenazine Completed NCT03698331 Phase 4 Valbenazine;Placebo oral capsule
8 Validation of Dyskinesia Rating Scales Completed NCT01071395 Phase 4 Amantadine;Placebo
9 D-serine Adjuvant Treatment for Parkinson's Disease Completed NCT00215904 Phase 4 D-serine (~2g/day)
10 A Randomized Controlled Trial of Risperidone and Olanzapine for the Schizophrenic Patients With Neuroleptic-Induced Tardive Dyskinesia Completed NCT00621998 Phase 4 risperidone;olanzapine
11 Tardive Dyskinesia and Cognitive Function Completed NCT00926965 Phase 4 amisulpride;Olanzapine;Conventional antipsychotics
12 Evaluation of the Long-term Effects of Amantadine in Parkinsonian's Suffering From Dyskinesia Induced by Levodopa: Study Randomised Double-blind, Placebo - Cessation of a Chronic Prescription. STUDY AMANDYSK. Completed NCT00632762 Phase 4 mantadix
13 Treatment of Tardive Dyskinesia With Galantamine Completed NCT00164242 Phase 4 Galantamine
14 Augmentation of Clozapine With Paliperidone in the Treatment of Resistant Schizophrenia Randomized Controlled Study Completed NCT01279213 Phase 4 paliperidone clozapine
15 The Effect of Amantadine on Movement Disorder in Ataxia-Telangiectasia Completed NCT00950196 Phase 4 amantadine sulphate
16 Possible Role of Chloroquine in Conjunction to Prednisone to Induce a Complete Remission in the Treatment of Autoimmune Hepatitis: a Randomized Trial Completed NCT02463331 Phase 4 Chloroquine diphosphate;prednisone;azathioprine
17 DOUBLE-BLIND RANDOMIZED CLINICAL TRIAL WITH CHLOROQUINE VERSUS PLACEBO FOR MAINTENANCE OF REMISSION OF AUTOIMMUNE HEPATITIS Completed NCT01980745 Phase 4 Chloroquine diphosphate 250mg;Placebo
18 A Double-Blind, Randomised, Parallel-Group Comparison of Ethyl-Eicosapentaenoic Acid (Ethyl-EPA) Versus Placebo as Add-on Medication in Patients With Established Tardive Dyskinesia Completed NCT00114595 Phase 4 eicosapentaenoic acid
19 A Phase 4, Double-Blind, Placebo-Controlled, Randomized Withdrawal Study to Evaluate the Persistence of Effect and Safety of Valbenazine for the Treatment of Tardive Dyskinesia Recruiting NCT03891862 Phase 4 Valbenazine;Placebo oral capsule
20 Treatment in Advanced Parkinson's Disease: Continuous Intrajejunal Levodopa INfusion VErsus Deep Brain STimulation Recruiting NCT02480803 Phase 4 Continuous intrajejunal infusion of levodopa-carbidopa
21 Effect of Varenicline on Smoking Cessation in Patients With Schizophrenia: Evaluation of Antipsychotic Drug-Induced Neurological Symptoms as Correlates of Response Recruiting NCT03495024 Phase 4 Varenicline
22 The Effect of Deep Brain Stimulation of the Subthalamic Nucleus (STN-DBS) on Quality of Life in Comparison to Best Medical Treatment in Patients With Complicated Parkinson's Disease and Preserved Psychosocial Competence (EARLYSTIM-study) Active, not recruiting NCT00354133 Phase 4 Best Medical Treatment
23 Botulinum Toxin Type A (Botox) in the Management of Levodopa-Induced Peak-Dose Dyskinesias in Parkinson's Disease: A Double-Blind, Randomized, Placebo Controlled, Cross-Over Design Study Terminated NCT00477802 Phase 4
24 Open Label Prospective Study of High Dose Ropinirole for Motor Fluctuations and Dyskinesias in Advanced Parkinson's Disease Unknown status NCT00260793 Phase 3 Ropinirole Hydrochloride
25 Levetiracetam Treatment of Tardive Dyskinesia Completed NCT00291213 Phase 3 levetiracetam;placebo
26 A Randomized, Double-Blind, Placebo-Controlled Study of SD-809 (Deutetrabenazine) for the Treatment of Moderate to Severe Tardive Dyskinesia Completed NCT02195700 Phase 2, Phase 3 SD-809;Placebo
27 A Randomized, Double-Blind, Placebo-Controlled, Fixed-Dose Study of SD-809 (Deutetrabenazine) for the Treatment of Moderate to Severe Tardive Dyskinesia Completed NCT02291861 Phase 3 SD-809;Placebo
28 A Phase 3, Open-Label, Safety and Tolerability Study of NBI-98854 for the Treatment of Tardive Dyskinesia Completed NCT02405091 Phase 3 NBI-98854
29 A Two Year Phase IIIb Randomised, Multicenter, Double-blind, SINEMET Controlled, Parallel Group, Flexible Dose Study, to Assess the Effectiveness of Controlled Release Ropinirole add-on Therapy to L-dopa at Increasing the Time to Onset of Dyskinesia in Parkinson's Disease Subjects. Completed NCT00363727 Phase 3 ropinirole controlled-release (REQUIP CR) for RLS
30 A Double-Blind, Placebo-Controlled, Multicenter, Multinational Phase III Study to Evaluate the Safety and Efficacy of Sarizotan in Patients With Parkinson's Disease Suffering From Treatment-Associated Dyskinesia Completed NCT00105521 Phase 3 Sarizotan;Placebo
31 A Double-blind, Placebo-controlled, Multicenter, Multinational Phase III Study to Evaluate the Safety and Efficacy of Sarizotan HCl 1 mg b.i.d. in Patients With Parkinson's Disease Suffering From Treatment-associated Dyskinesia Completed NCT00105508 Phase 3 Sarizotan;Placebo
32 Open-Label, 12-Month Safety and Efficacy Study of Levodopa - Carbidopa Intestinal Gel in Levodopa-Responsive Parkinson's Disease Subjects Completed NCT00360568 Phase 3 Levodopa-carbidopa intestinal gel
33 A Double-Blind, Randomised, Parallel-Group Comparison of Extract of Ginkgo Biloba(EGB-761) Versus Placebo as Add-on Medication in Patients With Established Tardive Dyskinesia Completed NCT00672373 Phase 3 Extract of Ginkgo Biloba (EGb-761 capsules);Placebo
34 Open-Label Rollover Study for Continuing Valbenazine (NBI-98854) Administration for the Treatment of Tardive Dyskinesia Completed NCT02736955 Phase 3 Valbenazine
35 Double-blind, Placebo-controlled, Randomized, Multicentre Phase II/III Study to Evaluate the Efficacy and Safety of Lisuride, Applied Subcutaneously by Means of a Minipump in Patients With Advanced Parkinson's Disease Refractory to Conventional Oral Therapy Completed NCT00408915 Phase 3 Continuous Subcutaneous Lisuride Infusion
36 Multicenter, Placebo Controlled, Randomized, Double-Blinded Study: Coenzyme Q10 Nanodispersion Versus Placebo as Symptomatic Treatment in Parkinson's Disease Completed NCT00180037 Phase 3 Coenzyme Q10 Nanodispersion (Nanoquinone);Placebo
37 Extended Release Amantadine Safety and Efficacy Study in Levodopa-Induced Dyskinesia (EASED Study) Completed NCT01397422 Phase 2, Phase 3 ADS-5102 (extended release amantadine HCl)
38 Efficacy and Safety of ADS-5102 (Amantadine HCl) Extended Release Capsules for the Treatment of Levodopa Induced Dyskinesia in Parkinson's Disease Patients (EASE LID Study) Completed NCT02136914 Phase 3 ADS-5102
39 ADS-5102 (Amantadine HCl) Extended Release Efficacy and Safety Study in Parkinson's Disease Patients With Levodopa-Induced Dyskinesia (EASE LID 3 Study) Completed NCT02274766 Phase 3 ADS-5102
40 A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Parallel, Fixed-Dose Study to Assess the Efficacy, Safety, and Tolerability of NBI-98854 for the Treatment of Tardive Dyskinesia Completed NCT02274558 Phase 3 NBI-98854;Placebo
41 A 16-week, Double-Blind, Placebo-Controlled, Randomised, Parallel-Group, Multicentre, International Study to Evaluate the Efficacy and Safety of 40 mg/Day KW-6002 (Istradefylline) and That of Entacapone Versus Placebo as Treatment for Parkinson's Disease in Patients With Motor Response Complications on Levodopa Therapy. Completed NCT00199394 Phase 3 Istradefylline (KW-6002)
42 Deep Brain Stimulation for Parkinson's Disease Trial Completed NCT00053625 Phase 3
43 A 6-Month, Open-Label, Single-Arm Safety Study of Flexibly Dosed Paliperidone Extended Release (1.5 - 12 mg/Day) in the Treatment of Adolescents (12 to 17 Years of Age) With Schizophrenia Completed NCT00488319 Phase 3 Paliperidone ER
44 Study of Efficacy and Acceptability of Tetrabenazine in the Late Dyskinetic Syndrome With Neuroleptics: A Randomized, Parallel Group, Double-blind Placebo Controlled Multicentre Trial Completed NCT01543321 Phase 3 Tetrabenazine;Placebo
45 Therapeutic Use of Piracetam for Treatment of Patients Suffering From Tardive Dyskinesia: a Double Blind, Placebo-Controlled Crossover Study Completed NCT00190008 Phase 3 piracetam
46 Buspirone Treatment of Iatrogenic Dyskinesias in Advanced Parkinson' Disease. Multicenter, International, Placebo-controlled, Randomised, Double Blind Trial Recruiting NCT02617017 Phase 3 Buspirone;Placebo
47 A Randomized, Double-Blind, Placebo-Controlled Study of TEV-50717 (Deutetrabenazine) for the Treatment of Dyskinesia in Cerebral Palsy in Children and Adolescents Recruiting NCT03813238 Phase 3 Deutetrabenazine;Placebo
48 Long Term Aerobic Exercise to Slow Progression in Parkinson's Disease Recruiting NCT03808675 Phase 2, Phase 3
49 An Open-Label, Long-Term Safety Study of SD-809 (Deutetrabenazine) for the Treatment of Moderate to Severe Tardive Dyskinesia Active, not recruiting NCT02198794 Phase 3 SD-809;Placebo
50 Open-Label Safety Study of ADS-5102 (Amantadine HCl) Extended Release Capsules for the Treatment of Levodopa Induced Dyskinesia (LID) Active, not recruiting NCT02202551 Phase 3 ADS-5102

Search NIH Clinical Center for Lingual-Facial-Buccal Dyskinesia

Cochrane evidence based reviews: dyskinesias

Sources

Genetic Tests for Lingual-Facial-Buccal Dyskinesia

About this section

Genetic tests related to Lingual-Facial-Buccal Dyskinesia:

# Genetic test Affiliating Genes
1 Orofacial Dyskinesia 29
Sources

Anatomical Context for Lingual-Facial-Buccal Dyskinesia

About this section

MalaCards organs/tissues related to Lingual-Facial-Buccal Dyskinesia:

41
Brain, Subthalamic Nucleus, Lung, Testes, Liver, Bone, Cerebellum
Sources

Publications for Lingual-Facial-Buccal Dyskinesia

About this section

Articles related to Lingual-Facial-Buccal Dyskinesia:

(show top 50) (show all 262)
# Title Authors PMID Year
1
Novel mutations in KMT2B offer pathophysiological insights into childhood-onset progressive dystonia. 38
31165786 2019
2
Correction to: Novel mutations in KMT2B offer pathophysiological insights on childhood-onset progressive dystonia. 38
31388109 2019
3
Influence of magnesium supplementation and L-type calcium channel blocker on haloperidol-induced movement disturbances. 38
31374223 2019
4
18F-FDG PET/CT: an unexpected case of Huntington's disease. 38
31043171 2019
5
Phenomenology and clinical course of movement disorder in GNAO1 variants: Results from an analytical review. 38
30642806 2019
6
Anti-N-methyl-d-aspartate receptor encephalitis during pregnancy: A case report. 38
30788880 2019
7
Clinical Profile and Neuropsychiatric Outcome in Children with Anti-NMDAR Encephalitis. 38
30955001 2019
8
Severe tooth loss secondary to orofacial dyskinesias in anti-NMDA receptor encephalitis. 38
30846455 2019
9
A review for the pharmacological effect of lycopene in central nervous system disorders. 38
30616078 2019
10
Possible nitric oxide mechanism involved in the protective effect of L-theanine on haloperidol-induced orofacial dyskinesia. 38
30942195 2019
11
TLE1, a key player in neurogenesis, a new candidate gene for autosomal recessive postnatal microcephaly. 38
29758293 2018
12
Protective effect of hesperetin against haloperidol-induced orofacial dyskinesia and catalepsy in rats. 38
28641484 2018
13
Cannabidiol prevents haloperidol-induced vacuos chewing movements and inflammatory changes in mice via PPARγ receptors. 38
30217539 2018
14
Effect of Biperiden Treatment in Acute Orofacial and Extremity Dyskinesia With Methylphenidate Therapy. 38
28328695 2018
15
L-Theanine Decreases Orofacial Dyskinesia Induced by Reserpine in Rats. 38
29629512 2018
16
Anti-NMDA receptor encephalitis: still unknown and underdiagnosed by physicians and especially by psychiatrists? 38
29050531 2018
17
Dexmethylphenidate Extended Release-Associated Orofacial Dyskinesia in an Adolescent with Autism Spectrum Disorder After Prolonged Use. 38
29781724 2018
18
Acute-onset Orofacial Dyskinesia with a Single Low Dose of Oral Flupentixol: A Case Report. 38
29962578 2018
19
Pediatric NMDAR encephalitis: A single center observation study with a closer look at movement disorders. 38
29396169 2018
20
Protective Effect of L-Theanine on Haloperidol-Induced Orofacial. 38
29374957 2018
21
A review of the outcome of dental implant provision in individuals with movement disorders. 38
30109299 2018
22
Management of Refractory Orofacial Dyskinesia Caused by Anti-N-methyl-d-aspartate Receptor Encephalitis Using Botulinum Toxin. 38
29520252 2018
23
Efficacy and safety of AAV2 gene therapy in children with aromatic L-amino acid decarboxylase deficiency: an open-label, phase 1/2 trial. 38
30169182 2017
24
Resveratrol Protects Against Vacuous Chewing Movements Induced by Chronic Treatment with Fluphenazine. 38
28744755 2017
25
An unusual case of refractory status epilepticus in a young lady: anti-NMDA receptor encephalitis. 38
28974594 2017
26
Serial EEG Monitoring in a Patient With Anti-NMDA Receptor Encephalitis. 38
27821481 2017
27
Behavioral and neurochemical effects of alpha lipoic acid associated with omega-3 in tardive dyskinesia induced by chronic haloperidol in rats. 38
28329449 2017
28
[Early Diagnosis of Chorea-Acanthocytosis: Orofacial Dyskinesia, Epileptic Seizures, and HyperCKemia]. 38
28561176 2017
29
Influence of magnesium supplementation on movement side effects related to typical antipsychotic treatment in rats. 38
27816557 2017
30
Clozapine-Induced Microseizures, Orofacial Dyskinesia, and Speech Dysfluency in an Adolescent with Treatment Resistant Early Onset Schizophrenia on Concurrent Lithium Therapy. 38
28835863 2017
31
Brain Calcification and Movement Disorders. 38
28097511 2017
32
Methylmalonic Acidemia with Novel MUT Gene Mutations. 38
29158924 2017
33
Ginkgo biloba leaf extract and alpha-tocopherol attenuate haloperidol-induced orofacial dyskinesia in rats: Possible implication of antiapoptotic mechanisms by preventing Bcl-2 decrease and Bax elevation. 38
27823630 2016
34
NMDA-receptor associated encephalitis in a woman with mature cystic ovarian teratoma. 38
29733562 2016
35
Crocin prevents haloperidol-induced orofacial dyskinesia: possible an antioxidant mechanism. 38
27872703 2016
36
Anti-collapsin response mediator protein 5 encephalitis masquerading as a low-grade brain tumour. 38
27247429 2016
37
Agmatine attenuates reserpine-induced oral dyskinesia in mice: Role of oxidative stress, nitric oxide and glutamate NMDA receptors. 38
27306571 2016
38
Plasmodium falciparum and Mycoplasma pneumoniae co-infection presenting with cerebral malaria manifesting orofacial dyskinesia and haemophagocytic lymphohistiocytosis. 38
27609213 2016
39
Clinical variability of neuroacanthocytosis syndromes-a series of six patients with long follow-up. 38
27310290 2016
40
Harpagophytum Procumbens Ethyl Acetate Fraction Reduces Fluphenazine-Induced Vacuous Chewing Movements and Oxidative Stress in Rat Brain. 38
26732278 2016
41
Non-Wilsonian hepatolenticular degeneration: Clinical and MRI observations in four families from south India. 38
26765764 2016
42
Diminution of falsely elevated tumour markers following immunosuppression for systemic lupus erythematosus with neurological involvement. 38
27048397 2016
43
Beneficial effects of lycopene against haloperidol induced orofacial dyskinesia in rats: Possible neurotransmitters and neuroinflammation modulation. 38
26712377 2016
44
Beneficial effect of candesartan and lisinopril against haloperidol-induced tardive dyskinesia in rat. 38
24464858 2015
45
Orofacial Dyskinesia in Elderly. 38
30838247 2015
46
Determining Whether a Definitive Causal Relationship Exists Between Aripiprazole and Tardive Dyskinesia and/or Dystonia in Patients With Major Depressive Disorder: Part 1. 38
26348804 2015
47
Magnesium Supplementation Prevents and Reverses Experimentally Induced Movement Disturbances in Rats: Biochemical and Behavioral Parameters. 38
25686766 2015
48
Management of Edentulous Orofacial Dyskinesia. 38
26329418 2015
49
A New Alternative Drug With Fewer Adverse Effects in the Treatment of Sydenham Chorea: Levetiracetam Efficacy in a Child. 38
26166232 2015
50
Effect of ethanolic extract of Coriandrum sativum L. on tacrine induced orofacial dyskinesia. 38
26040026 2015
Sources

Variations for Lingual-Facial-Buccal Dyskinesia

About this section

ClinVar genetic disease variations for Lingual-Facial-Buccal Dyskinesia:

6
# Gene Variation Type Significance SNP ID GRCh37 Pos GRCh38 Pos
1 CSTB NM_000100.3(CSTB): c.202C> T (p.Arg68Ter) single nucleotide variant Pathogenic rs74315442 21:45194178-45194178 21:43774297-43774297
2 46;XX;t(2;14)(q21;q24.3)dn Translocation Uncertain significance
3 HERC2 NM_004667.5(HERC2): c.5045A> G (p.Asn1682Ser) single nucleotide variant Uncertain significance 15:28474681-28474681 15:28229535-28229535
4 RYR1 NM_000540.2(RYR1): c.1312G> C (p.Glu438Gln) single nucleotide variant Uncertain significance 19:38943526-38943526 19:38452886-38452886
Sources

Expression for Lingual-Facial-Buccal Dyskinesia

About this section
Search GEO for disease gene expression data for Lingual-Facial-Buccal Dyskinesia.
Sources

Pathways for Lingual-Facial-Buccal Dyskinesia

About this section

Pathways related to Lingual-Facial-Buccal Dyskinesia according to GeneCards Suite gene sharing:

(show all 11)
# Super pathways Score Top Affiliating Genes
1
Peptide ligand-binding receptors 66
Show member pathways
 13.19 XK DRD5 DRD4 DRD3 DRD2 DRD1
2
Circadian entrainment 37
Show member pathways
 12.67 DRD5 DRD4 DRD3 DRD2 DRD1
3
Beta-Adrenergic Signaling 64
Show member pathways
 12.42 DRD5 DRD4 DRD3 DRD2 DRD1
5
cAMP signaling pathway 37
11.98 DRD5 DRD2 DRD1
6
Dopamine-DARPP32 Feedback onto cAMP Pathway 64
11.91 DRD5 DRD4 DRD3 DRD2 DRD1
7
Long-term potentiation 37
Show member pathways
 11.78 DRD5 DRD4 DRD2 DRD1
8
Nicotine Pathway (Dopaminergic Neuron), Pharmacodynamics 61
Show member pathways
 11.64 DRD4 DRD3 DRD2
9
Monoamine GPCRs 1
Show member pathways
 11.4 DRD5 DRD4 DRD3 DRD2 DRD1
10
Microglia Activation During Neuroinflammation: Steady-State Microglia 65
11.15 DRD2 DRD1
11
DARPP-32 Phosphorylation 65
10.27 DRD5 DRD3 DRD2 DRD1
Sources

GO Terms for Lingual-Facial-Buccal Dyskinesia

About this section

Cellular components related to Lingual-Facial-Buccal Dyskinesia according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 integral component of plasma membrane GO:0005887 9.77 DRD5 DRD4 DRD3 DRD2 DRD1
2 glutamatergic synapse GO:0098978 9.56 DRD4 DRD3 DRD2 DRD1
3 integral component of presynaptic membrane GO:0099056 9.46 DRD2 DRD1
4 endocytic vesicle GO:0030139 9.43 DRD3 DRD2
5 integral component of postsynaptic membrane GO:0099055 9.4 DRD2 DRD1
6 GABA-ergic synapse GO:0098982 9.33 DRD3 DRD2 DRD1
7 dopaminergic synapse GO:0098691 9.32 DRD3 DRD2
8 ciliary membrane GO:0060170 9.13 DRD5 DRD2 DRD1
9 non-motile cilium GO:0097730 8.8 DRD5 DRD2 DRD1

Biological processes related to Lingual-Facial-Buccal Dyskinesia according to GeneCards Suite gene sharing:

(show top 50) (show all 60)
# Name GO ID Score Top Affiliating Genes
1 response to drug GO:0042493 9.89 DRD3 DRD2 DRD1
2 autophagy GO:0006914 9.86 VPS13A DRD3 DRD2
3 cellular calcium ion homeostasis GO:0006874 9.84 XK DRD5 DRD4 DRD3
4 locomotory behavior GO:0007626 9.83 VPS13A DRD3 DRD2 DRD1
5 social behavior GO:0035176 9.79 VPS13A DRD4 DRD3
6 visual learning GO:0008542 9.77 DRD3 DRD2 DRD1
7 associative learning GO:0008306 9.75 DRD5 DRD2 DRD1
8 negative regulation of blood pressure GO:0045776 9.74 DRD5 DRD3 DRD2
9 protein localization GO:0008104 9.73 VPS13A DRD2
10 G protein-coupled receptor signaling pathway, coupled to cyclic nucleotide second messenger GO:0007187 9.73 DRD4 DRD1
11 arachidonic acid secretion GO:0050482 9.73 DRD4 DRD3 DRD2
12 response to cocaine GO:0042220 9.73 DRD5 DRD3 DRD2 DRD1
13 learning GO:0007612 9.72 DRD3 DRD1
14 synapse assembly GO:0007416 9.72 DRD2 DRD1
15 adenylate cyclase-modulating G protein-coupled receptor signaling pathway GO:0007188 9.72 DRD3 DRD2
16 negative regulation of protein kinase B signaling GO:0051898 9.72 DRD3 DRD2
17 circadian regulation of gene expression GO:0032922 9.72 DRD3 DRD2
18 negative regulation of protein secretion GO:0050709 9.72 DRD4 DRD3 DRD2
19 adult locomotory behavior GO:0008344 9.71 DRD4 CSTB
20 regulation of synaptic vesicle exocytosis GO:2000300 9.71 DRD2 DRD1
21 positive regulation of cytokinesis GO:0032467 9.71 DRD3 DRD2
22 feeding behavior GO:0007631 9.7 DRD2 DRD1
23 activation of adenylate cyclase activity GO:0007190 9.7 DRD5 DRD1
24 adult walking behavior GO:0007628 9.7 DRD2 DRD1
25 response to morphine GO:0043278 9.7 DRD3 DRD2
26 behavioral fear response GO:0001662 9.69 DRD4 DRD1
27 temperature homeostasis GO:0001659 9.69 DRD2 DRD1
28 transmission of nerve impulse GO:0019226 9.69 DRD5 DRD1
29 prepulse inhibition GO:0060134 9.69 DRD3 DRD2 DRD1
30 adenylate cyclase-activating adrenergic receptor signaling pathway GO:0071880 9.68 DRD3 DRD2
31 long-term synaptic depression GO:0060292 9.68 DRD5 DRD1
32 striatum development GO:0021756 9.68 DRD2 DRD1
33 positive regulation of renal sodium excretion GO:0035815 9.67 DRD3 DRD2
34 grooming behavior GO:0007625 9.67 DRD2 DRD1
35 adenylate cyclase-inhibiting dopamine receptor signaling pathway GO:0007195 9.67 DRD4 DRD3 DRD2
36 regulation of postsynaptic neurotransmitter receptor internalization GO:0099149 9.66 DRD4 DRD3
37 G protein-coupled receptor internalization GO:0002031 9.66 DRD3 DRD2
38 regulation of dopamine metabolic process GO:0042053 9.65 DRD4 DRD1
39 peristalsis GO:0030432 9.65 DRD2 DRD1
40 negative regulation of voltage-gated calcium channel activity GO:1901386 9.65 DRD4 DRD2
41 adenylate cyclase-activating dopamine receptor signaling pathway GO:0007191 9.65 DRD5 DRD3 DRD1
42 behavioral response to ethanol GO:0048149 9.64 DRD4 DRD2
43 mating behavior GO:0007617 9.64 DRD5 DRD1
44 cellular response to catecholamine stimulus GO:0071870 9.63 DRD5 DRD1
45 cerebral cortex GABAergic interneuron migration GO:0021853 9.63 DRD2 DRD1
46 phospholipase C-activating dopamine receptor signaling pathway GO:0060158 9.63 DRD5 DRD2 DRD1
47 negative regulation of dopamine receptor signaling pathway GO:0060160 9.62 DRD3 DRD2
48 behavioral response to cocaine GO:0048148 9.62 DRD4 DRD3 DRD2 DRD1
49 regulation of locomotion involved in locomotory behavior GO:0090325 9.61 DRD3 DRD2
50 positive regulation of dopamine uptake involved in synaptic transmission GO:0051586 9.61 DRD4 DRD2

Molecular functions related to Lingual-Facial-Buccal Dyskinesia according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 G protein-coupled receptor activity GO:0004930 9.77 DRD5 DRD4 DRD3 DRD2 DRD1
2 drug binding GO:0008144 9.5 DRD4 DRD3 DRD2
3 G-protein alpha-subunit binding GO:0001965 9.43 DRD5 DRD1
4 adrenergic receptor activity GO:0004935 9.4 DRD3 DRD2
5 dopamine binding GO:0035240 9.35 DRD5 DRD4 DRD3 DRD2 DRD1
6 dopamine neurotransmitter receptor activity, coupled via Gi/Go GO:0001591 9.33 DRD4 DRD3 DRD2
7 dopamine neurotransmitter receptor activity, coupled via Gs GO:0001588 9.26 DRD5 DRD1
8 dopamine neurotransmitter receptor activity GO:0004952 9.02 DRD5 DRD4 DRD3 DRD2 DRD1
Sources

Sources for Lingual-Facial-Buccal Dyskinesia

About this section
3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 TGDB
71 Tocris
72 UMLS
73 UMLS via Orphanet
The MalaCards human disease database index: 1-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Content
Loading form....